Literature DB >> 31515251

A KLF4-DYRK2-mediated pathway regulating self-renewal in CML stem cells.

Chun Shik Park1, Andrew H Lewis1,2, Taylor J Chen1,2, Cory S Bridges1, Ye Shen1,2, Koramit Suppipat3, Monica Puppi1, Julie A Tomolonis4, Paul D Pang2, Toni-Ann Mistretta1, Leyuan Ma5, Michael R Green5, Rachel Rau6, H Daniel Lacorazza1.   

Abstract

Leukemia stem cells are a rare population with a primitive progenitor phenotype that can initiate, sustain, and recapitulate leukemia through a poorly understood mechanism of self-renewal. Here, we report that Krüppel-like factor 4 (KLF4) promotes disease progression in a murine model of chronic myeloid leukemia (CML)-like myeloproliferative neoplasia by repressing an inhibitory mechanism of preservation in leukemia stem/progenitor cells with leukemia-initiating capacity. Deletion of the Klf4 gene severely abrogated the maintenance of BCR-ABL1(p210)-induced CML by impairing survival and self-renewal in BCR-ABL1+ CD150+ lineage-negative Sca-1+ c-Kit+ leukemic cells. Mechanistically, KLF4 repressed the Dyrk2 gene in leukemic stem/progenitor cells; thus, loss of KLF4 resulted in elevated levels of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2), which were associated with inhibition of survival and self-renewal via depletion of c-Myc protein and p53 activation. In addition to transcriptional regulation, stabilization of DYRK2 protein by inhibiting ubiquitin E3 ligase SIAH2 with vitamin K3 promoted apoptosis and abrogated self-renewal in murine and human CML stem/progenitor cells. Altogether, our results suggest that DYRK2 is a molecular checkpoint controlling p53- and c-Myc-mediated regulation of survival and self-renewal in CML cells with leukemic-initiating capacity that can be targeted with small molecules.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31515251      PMCID: PMC6887114          DOI: 10.1182/blood.2018875922

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  68 in total

1.  KLF4 translation level is associated with differentiation stage of different pediatric leukemias in both cell lines and primary samples.

Authors:  Xiaoping Guo; Yongmin Tang
Journal:  Clin Exp Med       Date:  2012-05-17       Impact factor: 3.984

2.  Role for DYRK family kinases on regulation of apoptosis.

Authors:  Kiyotsugu Yoshida
Journal:  Biochem Pharmacol       Date:  2008-07-02       Impact factor: 5.858

3.  The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene.

Authors:  Benjamin D Rowland; René Bernards; Daniel S Peeper
Journal:  Nat Cell Biol       Date:  2005-11       Impact factor: 28.824

4.  Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.

Authors:  Stéphane Prost; Francis Relouzat; Marc Spentchian; Yasmine Ouzegdouh; Joseph Saliba; Gérald Massonnet; Jean-Paul Beressi; Els Verhoeyen; Victoria Raggueneau; Benjamin Maneglier; Sylvie Castaigne; Christine Chomienne; Stany Chrétien; Philippe Rousselot; Philippe Leboulch
Journal:  Nature       Date:  2015-09-02       Impact factor: 49.962

5.  ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis.

Authors:  Maria Anna Zipeto; Angela C Court; Anil Sadarangani; Nathaniel P Delos Santos; Larisa Balaian; Hye-Jung Chun; Gabriel Pineda; Sheldon R Morris; Cayla N Mason; Ifat Geron; Christian Barrett; Daniel J Goff; Russell Wall; Maurizio Pellecchia; Mark Minden; Kelly A Frazer; Marco A Marra; Leslie A Crews; Qingfei Jiang; Catriona H M Jamieson
Journal:  Cell Stem Cell       Date:  2016-06-09       Impact factor: 24.633

6.  Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib.

Authors:  Ling Li; Lisheng Wang; Liang Li; Zhiqiang Wang; Yinwei Ho; Tinisha McDonald; Tessa L Holyoake; WenYong Chen; Ravi Bhatia
Journal:  Cancer Cell       Date:  2012-02-14       Impact factor: 31.743

7.  Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression.

Authors:  Linsey Reavie; Shannon M Buckley; Evangelia Loizou; Shoichiro Takeishi; Beatriz Aranda-Orgilles; Delphine Ndiaye-Lobry; Omar Abdel-Wahab; Sherif Ibrahim; Keiichi I Nakayama; Iannis Aifantis
Journal:  Cancer Cell       Date:  2013-03-18       Impact factor: 31.743

Review 8.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113

9.  Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.

Authors:  Xing Guo; Xiaorong Wang; Zhiping Wang; Sourav Banerjee; Jing Yang; Lan Huang; Jack E Dixon
Journal:  Nat Cell Biol       Date:  2015-12-14       Impact factor: 28.824

10.  Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells.

Authors:  Sheela A Abraham; Lisa E M Hopcroft; Emma Carrick; Mark E Drotar; Karen Dunn; Andrew J K Williamson; Koorosh Korfi; Pablo Baquero; Laura E Park; Mary T Scott; Francesca Pellicano; Andrew Pierce; Mhairi Copland; Craig Nourse; Sean M Grimmond; David Vetrie; Anthony D Whetton; Tessa L Holyoake
Journal:  Nature       Date:  2016-06-08       Impact factor: 49.962

View more
  13 in total

1.  Krüppel-like Factor 4 Supports the Expansion of Leukemia Stem Cells in MLL-AF9-driven Acute Myeloid Leukemia.

Authors:  Andrew Henry Lewis; Cory Seth Bridges; David Neal Moorshead; Taylor J Chen; Wa Du; Barry Zorman; Pavel Sumazin; Monica Puppi; H Daniel Lacorazza
Journal:  Stem Cells       Date:  2022-08-25       Impact factor: 5.845

2.  Inducible transgene expression in PDX models in vivo identifies KLF4 as a therapeutic target for B-ALL.

Authors:  Wen-Hsin Liu; Paulina Mrozek-Gorska; Anna-Katharina Wirth; Tobias Herold; Larissa Schwarzkopf; Dagmar Pich; Kerstin Völse; M Camila Melo-Narváez; Michela Carlet; Wolfgang Hammerschmidt; Irmela Jeremias
Journal:  Biomark Res       Date:  2020-09-16

Review 3.  Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future.

Authors:  Valentina R Minciacchi; Rahul Kumar; Daniela S Krause
Journal:  Cells       Date:  2021-01-10       Impact factor: 6.600

Review 4.  Recent Discoveries on the Involvement of Krüppel-Like Factor 4 in the Most Common Cancer Types.

Authors:  Agnieszka Taracha-Wisniewska; Grzegorz Kotarba; Sebastian Dworkin; Tomasz Wilanowski
Journal:  Int J Mol Sci       Date:  2020-11-22       Impact factor: 5.923

Review 5.  DYRK2 controls a key regulatory network in chronic myeloid leukemia stem cells.

Authors:  Chun Shik Park; H Daniel Lacorazza
Journal:  Exp Mol Med       Date:  2020-10-16       Impact factor: 8.718

Review 6.  Emerging roles of DYRK2 in cancer.

Authors:  Vasudha Tandon; Laureano de la Vega; Sourav Banerjee
Journal:  J Biol Chem       Date:  2021-01-07       Impact factor: 5.157

Review 7.  The Impact of Iron Chelators on the Biology of Cancer Stem Cells.

Authors:  Julia Szymonik; Kamila Wala; Tomasz Górnicki; Jolanta Saczko; Bartosz Pencakowski; Julita Kulbacka
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

8.  3,3'-Diindolylmethane Enhances Paclitaxel Sensitivity by Suppressing DNMT1-Mediated KLF4 Methylation in Breast Cancer.

Authors:  Fenfen Xiang; Zhaowei Zhu; Mengzhe Zhang; Jie Wang; Zixi Chen; Xiaoxiao Li; Tao Zhang; Qing Gu; Rong Wu; Xiangdong Kang
Journal:  Front Oncol       Date:  2021-06-03       Impact factor: 6.244

9.  [Targeted next-generation sequencing for the molecular diagnosis of patients with chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitor].

Authors:  W E Wu; X Zhou; N Xu; J X Huang; L Liu; Y X Tan; J Luo; J Y Qin; C X Yin; L L Zhou; X L Liu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-10-14

Review 10.  Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.

Authors:  Mattias F Lindberg; Laurent Meijer
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.